Neurocrine breaks out proof-of-concept data for CAH drug; Akebia, MTPC work toward Japanese NDA after anemia drug scores in twin PhIIIs
→ More than a month after its big ticket deal with Voyager Therapeutics $VYGR, Neurocrine Biosciences $NBIX announced positive interim data from a Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
